ASCO 2018 | Is immunotherapy cost-effective?

Rafael Fonseca

One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses whether it is cost-effective for patients to receive monoclonal antibody therapy. Dr Fonseca then states that pharmacoeconomic analyses are much more complex than most people consider. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video